| Ident. | Authors (with country if any) | Title |
|---|
| 000239 |
Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Negre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarie [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France] | A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease |
| 000261 |
Patrick Lemoine [France] | Pharmacologie de l'âme ou le mystère du placebo |
| 000368 |
Santiago Perezlloret [Argentine, France] ; Gabriela Nano [Argentine] ; Andrea Carrosell [Argentine] ; Elkan Gamzu [États-Unis] ; Marcelo Merello [Argentine] | A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients |
| 000452 |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and Efficacy of Perampanel in Advanced Parkinson's Disease: A Randomized, Placebo-Controlled Study |
| 000472 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Cesaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible Sublingual Piribedil to Abort OFF Episodes: A Single Dose Placebo-Controlled, Randomized, Double-Blind, Cross-Over Study |
| 000520 |
Emmanuelle Pourcher [Canada, France] ; Sophie Remillard [Canada] ; Henri Cohen [Canada, France] | Affect in Parkinson's disease: validation of the two-factor approach |
| 000525 |
Joaquim J. Ferreira [Portugal] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; José-Francisco Rocha [Portugal] ; Teresa Nunes [Portugal] ; Luis Almeida [Portugal] ; Patrício Soares-Da-Silva [Portugal] | A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease |
| 000644 |
Joëlle Micallef [France] ; Marc Rey [France] ; Alexandre Eusebio [France] ; Christine Audebert [France] ; Frank Rouby [France] ; Elisabeth Jouve [France] ; Sophie Tardieu [France] ; Oliver Blin [France] | Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects |
| 000728 |
Daniel Hamack [Allemagne] ; Wassilios Meissner [France] ; Julia A. Jira [Allemagne] ; Christine Winter [Allemagne] ; Rudolf Morgenstern [Allemagne] ; Andreas Kupsch [Allemagne] | Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism |
| 000729 |
Christopher G. Goetz [États-Unis] ; Eugene Laska [États-Unis] ; Christine Hicking [Allemagne] ; Philippe Damier [France] ; Thomas Müller [Allemagne] ; John Nutt [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Placebo Influences on Dyskinesia in Parkinson's Disease |
| 000798 |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Wemer Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline as a Disease Modifying Therapy in Parkinson's Disease (The ADAGIO Study) : Rationale, Design, and Baseline Characteristics |
| 000853 |
Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Sarizotan as a treatment for dyskinesias in Parkinson's disease : A double-blind placebo-controlled trial |
| 000854 |
Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France] | Safety and tolerability of growth hormone therapy in multiple system atrophy : A double-blind, placebo-controlled study |
| 000917 |
Pauline Delaveau [France] ; Pilar Salgado-Pineda [France] ; Joëlle Micallef-Roll [France] ; Olivier Blin [France] | Amygdala activation modulated by levodopa during emotional recognition processing in healthy volunteers : A double-blind, placebo-controlled study |
| 000C13 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study |
| 001636 |
O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell | Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease |
| 001741 |
P. Limousin [France] ; P. Pollak [France] ; J. P. Pfeffen ; C. L. Tournier-Gervason [France] ; R. Dubuis ; J. E. Perret [France] | Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease |
| 001B25 |
H. Allain ; J. Denmat ; D. Bentue-Ferrer ; D. Milon ; P. Pignol ; J. M. Reymann ; D. Pape ; O. Sabouraud ; J. Van Den Driessche | Randomized, double-blind trial of exifone versus cognitive problems in Parkinson's disease |
